Tech Company Financing Transactions
Metsera Funding Round
On 11/14/2024, Metsera announced $215 million in Series B funding from Venrock, Wellington Management Company and Alpha Wave Ventures.
Transaction Overview
Company Name
Announced On
11/14/2024
Transaction Type
Venture Equity
Amount
$215,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to further advance its portfolio of clinical-stage, Nutrient-Stimulated Hormone (NuSH) analog peptides.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
3 World Trade Center
New York, NY 10007
USA
New York, NY 10007
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Metsera is a clinical-stage biopharmaceutical company dedicated to leading the next generation of medicines and solutions for obesity and metabolic diseases. Founded by Population Health Partners and ARCH Venture Partners, Metsera is accelerating new medicines with potential best-in-class profiles from a proprietary library of more than 20,000 incretin and non-incretin peptides and monoclonal antibodies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Whit Bernard
Browse more venture capital transactions:
Prev: 11/14/2024: Influur venture capital transaction
Next: 11/14/2024: SwiftConnect venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs